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Survival Increase with Autologous, Hapten-Modified Melanoma Vaccine (M-Vax)
D Berd
AVAX Technologies, Inc. and Thomas Jefferson University, Philadelphia, PA, USA
We have devised a novel approach to the immunotherapy of cancer based on
modification of autologous tumor cells with the hapten, dinitrophenyl (DNP). This
technology is being developed by AVAX Technologies as a treatment for melanoma
under the brand name, M-Vax. The treatment program consists of multiple
intradermal injections of DNP-modified autologous tumor cells mixed with BCG
(bacille Calmette Guerin) as an immunological adjuvant. Administration of DNP-
vaccine to patients with metastatic melanoma induces a unique reaction – the
development of inflammation in metastatic masses. Following DNP-vaccine
treatment, almost all patients develop delayed-type hypersensitivity (DTH) to
autologous, DNP-modified melanoma cells; about half also exhibit DTH to
autologous, unmodified tumor cells. The toxicity of the vaccine is mild, consisting
mainly of papules or pustules at the injection sites. Clinical trials have been
conducted in two populations of melanoma patients: stage IV with measurable
metastases, and clinical stage III patients rendered tumor-free by lymphadenect-
omy. In 83 patients with measurable metastases, there were 11 anti-tumor
responses: 2 complete, 4 partial, and 5 mixed. In 214 stage III patients the 5-year
overall survival rate was 44%, which compares favorably to the reported surgical
rate of 20–25%. In both populations, the induction of DTH to unmodified
autologous tumor cells was associated with significantly longer survival. This is a
platform technology that is adaptable to other human cancers, including non-small
cell lung cancer, ovarian and renal cell carcinomas.
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Interferon and Melanoma: A Wedding with Ups and Downs
N Pimpinelli
Department of Dermatological Sciences, University of Florence Medical School,
Florence, Italy
High dose alpha-2 recombinant interferon (aIFN) - according to the so-called
Kirkwood regimen — is to date the only adjuvant treatment which demonstrated a
clear-cut benefit in disease-free survival (DFS) of stage IIB and III melanoma
patients, even though results in stage IIB patients are biased by the lacking
availability of sentinel node biopsy data in part of the patients. Ongoing clinical
trials with pulsed i.v. high dose aIFN treatment have been designed in order to
maximize the anti-proliferative efficacy on residual tumor while minimizing the
side effects and impact on the quality of life. Notwithstanding the lack of evidence-
based data about the benefit of low dose aIFN adjuvant treatment, there is an
increasing attention to the possible crucial interference of aIFN with a genetically
modulated, specific immune response and the angiogenic properties of tumor cells.
In this case, the length and schedule of treatment could be of much higher
importance as compared to the dose. This latter consideration also affects the use
and possible benefit of aIFN in stage IV melanoma patients.
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Genetic Testing and Imaging Technique
S Puig
Melanoma Unit, Dermatology Department, Hospital Clinic, Barcelona, Spain
Nearly 10% of cutaneous melanoma (CM) occurs in a familial setting. Two main
genes involved in melanoma susceptibility have been described. The first,
CDKN2A, located on chromosome 9p21, encodes two distinct proteins: p16INK4A
and p14ARF both involved in inhibition of cell cycle. The second melanoma
susceptibility gene, cyclin-dependent kinase 4 (CDK4), is mutated in less than 1%
of families. Germline CDKN2A mutations have been described in 10–50% of
families from several countries. But CDKN2A germline mutations have also been
described in patients with more than one primary CM (MPM) (8.3–15% of MPM
patients). The risk to identify a CDKN2A mutation increased with the number of
primary melanomas, the early age of onset and the presence of familial history of
melanoma and/or pancreatic cancer. Dysplastic nevi (DN) are also observed in
many of familial cases or MPMs. This is probably more frequent repuent than we
would expect to observe in sporadic melanoma suggesting that the ‘‘DN’’
phenotype may be a co-factor that contributes to the development of multiple
melanomas. Knowledge of the likelihood of detecting CDKN2A mutations has
particular relevance for clinical screening of patients and their families. In a
personal study, the molecular identification of CDKN2A mutation carriers, and
their clinical screening with dermoscopy and digital follow-up, quickly resulted in
the detection of early melanomas in our clinic that would normally have been
detected much later. This underlines the importance of mutational screening and
regular and thorough dermatological screening of relatives of individuals harboring
germline CDKN2A mutations, for earliest MM diagnosis. However, as we detected
melanoma also in relatives of families not carrying a CDKN2A mutation,
dermatological screening, sun exposure avoidance and self-examination are
encouraged to relatives of familial melanoma and/or MPM patients without
mutation in CDKN2A.
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Advantages of Digital Dermatology in Clinical Practice
J Ola´h
Department of Dermatology and Allergology, University of Szeged, Hungary
With the increasing incidence of melanoma worldwide, the differential diagnosis of
pigmented tumours became one of the most important questions in dermatological
practice. The dermoscopy was the first milestone introduced in the diagnostic
procedure of malignant melanoma. In the last decade a growing interest has
developed in automated analysis of digitized images obtained by digital
dermoscopy technique to assist clinicians in differentiating early melanoma from
benign skin lesions. The computer-aided assessment of melanocytic skin lesions
offers the dermatologist considerable assistance in evaluating suspicious pigmented
skin lesions. The computer digital analysis can be successfully applied when the
lesions are flat, with dimensions included within 5–12 mm in diameter, just as the
feature of malignant melanoma is in early stages of development. The digital
standardized dermoscopic point score must always be correlated with the patient’s
history, the clinical nature of the lesion and the conventional dermoscopic
assessment. Digital dermoscopy systems make it easy for clinician to send the
dermatopathologist standardized images of pigmented skin lesions, improving the
reliability of dermatopathological diagnosis. The use of digital dermoscopic systems
has a very powerful impact on the follow-up examinations of patients with multiple
atypical moles. During the monitoring period current and past images can be
compared precisely, the presence or absence of even minor changes can be
documented. Digital dermoscopy is helpful not only in the diagnostic procedures,
but also in gradual dermatological education, in self training and teledermatology.
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Metallothioneins as a Prognostic Marker in Primary Melanoma
G Weinlich, E Hassler, M Baltaci, K Eisendle, P Fritsch and B Zelger
Clinical Department of Dermatology and Venerology, Medical University of
Innsbruck, Innsbruck, Austria
Metallothioneins (MT) are ubiquitous, cystein-rich intracellular small proteins with
high affinity for heavy metal ions such as zinc, copper or cadmium. In the last
decades it could be shown, that MT-overexpression in a variety of cancers is
associated with resistance to anticancer drugs and is combined with poor
prognosis. In a prospective study we examined the role of MT overexpression in
melanoma patients as a prognostic factor for progression and survival. Between
1993 and 2004, 3386 patients with primary cutaneous melanoma were
investigated by using a monoclonal antibody against MT on routinely fixed,
paraffin-embedded tissues. 1270 patients with invasive tumors could be followed
up for further statistical analysis (Fisher’s exact test, Mantel-Haenszel’s test, Kaplan-
Meier curves). The MT data of disease-free interval and overall-survival were
compared univariately and multivariately in Cox regression analysis. Immunohis-
tochemical overexpression of MT in the tumor cells of patients with primary
melanoma (310/1270; 24.4%) was associated with a higher risk for progression
(117/167; 70.1%) and reduced survival (80/110; 72.7%) of the disease (both p o
0.0001). Similarly, Kaplan-Meier curves gave highly significant disadvantages for
the MT-positive group. Univariate analysis (relative risk 7.4; CI 95% 5.2–10.2; po
0.0001 for disease free survival and relative risk 7.1; CI 95% 4.7–10.9; po 0.0001
for overall survival), as well as multivariate analysis with other prognostic markers,
turned MT-overexpression out as a highly significant and independent factor for
estimating the prognosis in primary melanoma patients, even in patients with low
risk melanomas.
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Out-door Work as Potential Risk for Melanoma?
R Strohal1, W Unterberger2, J Linemayr2, M Mittlbo¨ck3 and G Payer-Neundlinger2
1Department of Dermatology, Federal University Teaching Hospital Feldkirch,
Germany, 2Austria Centre of Occupational Health, OMV Solutions, Vienna, Austria
and 3Core Unit for Medical Statistics and Informatics, Medical University of
Vienna, Austria
Melanoma prevention programmes have become increasingly important. However,
at this point, these initiatives are exclusively designed for the public and no
systematic approach exists for those who undergo occupational sun exposure. To
clarify the necessity of such a programme for the industry, we analysed 1.442
employees of the Austrian Mineral Oil Association working either outdoor, indoor,
or both. By using a questionnaire and examinations by a dermatologists, we defined
and correlated work place/life style and skin related melanoma risk factors. The
general melanoma risk of the whole study cohort (Clark nevi in 4.4%, workers with
nevi fulfilling at least one of the ABCD criteria in 20.5%) corresponded to the
situation of the general public. By comparing the different out-door and in-door
study cohorts, significant differences in the work/life style related, but no substantial
differences in the skin related melanoma risk factors were detected. With the
general amount of UV-exposure as the leading cause for a high melanoma risk, the
outdoor group seemed to generate their level of risk by occupational sun exposure,
frequent leisure time outdoor activities and the general lack of any sun protection
measures, while the office workers showed a high frequency of sun bed visits and
holidays in the south/mountains. Taken together, we showed for the first time that
discontinuous as well as (occupation associated) continuous UV-exposure is
mainly and equally important for the development of skin related melanoma risk
factors. Consequently, we propose the need of additional melanoma prevention
programmes specifically designed for the affected industries.
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